BELGRADE, Mont., Jan. 11 /PRNewswire/ -- Bacterin International, Inc., a developer and manufacturer of elutive bioactive coatings for medical devices, completed its first sale of a Bacterin-branded medical device, the Via(TM) Wound Drain. This is the first medical device available today that carries the Bacterin name brand.
Via(TM) is a fully channeled silicone surgical wound drain designed to improve patient safety and comfort. Via(TM) is composed of flexible silicone and a low profile connector used to minimize tissue trauma and discomfort. The wound drain has a four channel design that minimizes the risk of occlusion, high tensile strength minimizing the risk of fragmentation, and a radiopaque dye for easy visualization. The Via(TM) Wound Drain series consists of round drains, available in three sizes, and flat drains, available in two sizes.
“This initial sale represents a significant milestone in Bacterin’s pursuit of developing and manufacturing safer and more effective medical devices,” said Dr. Mike Johnson, Vice President of Quality, Clinical, and Regulatory Affairs. “This is just one of many products we plan on developing to enhance patient care.” The Elutia(TM) Wound Drain series (a second generation drain) will be coated with an antimicrobial using Bacterin’s proprietary coating technologies. Elutia(TM) is currently in late stage development and will be available to market later in 2006.
Bacterin is a pioneer in biofilm science and the industry’s leading independent biofilm testing facility for the world’s largest medical device manufacturers. The company is also manufacturing and licensing its own proprietary bioactive coating technology suitable for a variety of medical device applications. Bacterin’s anti-infective coating prevents microbial (biofilm) attachment and growth, thus significantly reducing bacterial adhesion associated with invasive medical devices. Bacterin’s bioactive coating technology can be applied to devices requiring antimicrobial, anti-inflammatory, analgesic, anticoagulant, or pain control compounds that can be released immediately or over time.
As a means of complimenting its core coatings business, Bacterin has established a Biologics Division, with a focus on utilization of Bacterin’s coating technologies to enhance human allograft tissues. Bacterin Biologics currently has an array of allografts available with the Bacterin name, including the trademarked OsteoSponge(TM). While Bacterin is still a privately held company, it is in discussion with financial institutions regarding a path towards a publicly traded company. For more information, visit www.bacterin.com.
Bacterin International, Inc.
CONTACT: Guy Cook, President, GCook@bacterin.com, or Molly Mason, InvestorRelations, mmason@bacterin.com, both of Bacterin International, Inc.,+1-406-388-0480
Web site: http://www.bacterin.com/
